Chengliang Xie

Angiotensin I-converting enzyme inhibitor derived from cross-linked oyster protein.

Following cross-linking by microbial transglutaminase, modified oyster proteins were hydrolyzed to improve inhibitory activity against angiotensin-converting enzyme (ACE) inhibitory activity with the use of a single protease, or a combination of six proteases. The oyster hydrolysate with the lowest 50% ACE inhibitory concentration (IC50) of 0.40 mg/mL was obtained by two-step hydrolysis of the cross-linked oyster protein using Protamex and Neutrase. Five ACE inhibitory peptides were purified from the oyster hydrolysate using a multistep chromatographic procedure comprised of ion-exchange, size exclusion, and reversed-phase liquid chromatography. Their sequences were identified as TAY, VK, KY, FYN, and YA, using automated Edman degradation and mass spectrometry. These peptides were synthesized, and their IC50 values were measured to be 16.7, 29.0, 51.5, 68.2, and 93.9 μM, respectively. Toxicity of the peptides on the HepG2 cell line was not detected. The oyster hydrolysate also significantly decreased the systolic blood pressure of spontaneously hypertensive rats (SHR). The antihypertensive effect of the oyster hydrolysate on SHR was rapid and long-lasting, compared to commercially obtained sardine hydrolysate. These results suggest that the oyster hydrolysate could be a source of effective nutraceuticals against hypertension.

Fermented soy-powder milk with Lactobacillus plantarum P1201 protects against high-fat diet-induced obesity

Summary Fermented soy-powder milk (FSPM) with Lactobacillus plantarum P1201 contains more conjugated linoleic acid (CLA) and isoflavone aglycones compared with unfermented soy-powder milk (UFSPM). In this study, the antiobesity effect of FSPM was investigated in a high-fat diet (HFD)-induced obesity model. Results showed that FSPM reduced the weight of body, body weight gain, liver and mesenteric white adipose tissue by 10.7%, 17.7%, 32.8% and 24.1%, respectively, compared with the HFD group. Meanwhile, FSPM suppressed the HFD-induced increase of serum parameters such as total and low-density lipoprotein, cholesterol, alanine transaminase, glucose and c-peptide. To investigate how FSPM ameliorated obesity, several lipid metabolism and inflammation-related genes in liver were analysed. FSPM significantly ameliorated HFD-induced hepatic steatosis by down-regulating peroxisome proliferator-activated receptor gamma, lipoprotein lipase, fatty acid synthase, acetyl CoA carboxylase, adipocyte fatty acid-binding protein, tumour necrosis factor alpha and interleukin 1 beta. Our results showed FSPM can protect against HFD-induced obesity.

Reduction of Asthmatic Parameters by Sea Hare Hydrolysates in a Mouse Model of Allergic Asthma

Sea hare has a variety of biological activities. However, little is known regarding the anti-asthmatic effects of sea hare. This study was performed to identify the effect of sea hare hydrolysates (SHH) on an ovalbumin (OVA)-induced allergic asthma model. The experimental asthma model was sensitized and challenged with OVA. We found that a high-dose of SHH (HSHH) significantly inhibited OVA-induced airway inflammation and mucus production around the airway in lung sections, while low- and medium-dose SHH showed an insignificant effect. In addition, HSHH highly reduced OVA-induced production of interleukin-4, -5, -13, leukotriene D4, E4, and histamine in bronchoalveolar lavage fluid. HSHH decreased the histamine-induced increase in the intracellular Ca2+ level and contractions in asthmatic smooth muscle cells. Furthermore, HSHH did not affect the weights of the spleen nor thymus, whereas dexamethasone (DEX), a steroidal anti-inflammatory drug, reduced them. Taken together, these results showed that HSHH reduced asthmatic parameters in a mouse model of allergic asthma, and suggest that SHH could be used as a potential therapeutic agent for asthma.